Feldman R. Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act.
PLoS Med 2024;
21:e1004381. [PMID:
38662775 PMCID:
PMC11081489 DOI:
10.1371/journal.pmed.1004381]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Revised: 05/09/2024] [Indexed: 05/12/2024] Open
Abstract
In this Policy Forum piece, Robin Feldman discusses how current legislation contributes to informational deficits around drug patents for biologic drugs in the United States.
Collapse